Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Non-interventional Study of Lenalidomide (Revlimid®) in Combination With Dexamethasone as First Line Therapy in Transplant-ineligible Patients With Multiple Myeloma

NCT02537808 is registered in ClinicalTrials.gov with iOMEDICO AG as lead sponsor.

NCT NCT02537808
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02537808 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Non-interventional Study of Lenalidomide (Revlimid®) in Combination With Dexamethasone as First Line Therapy in Transplant-ineligible Patients With Multiple Myeloma
Lead sponsor
iOMEDICO AG
Phase
Observational
Overall status
Completed
Start date
June 23, 2015
Completion date
September 13, 2023
Enrollment
172 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

multiple myeloma